[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370150-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370150-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","tumor-cell-based-liquid-biopsy-using-highthroughput-microfluidic-enrichment-of-entire-leukapheresis-product-received-date-information","Tumor cell-based liquid biopsy using highthroughput microfluidic enrichment of entire leukapheresis product - Received date information","","Tumor cell-based liquid biopsy addresses limited clinical utility of circulating tumor cells (CTCs), which are rare and therefore constrain quantitative, cell-level analysis. The study introduces a highthroughput microfluidic device that depletes hematopoietic cells using high-flow channels and force-amplifying magnetic lenses, enabling epitope-agnostic interrogation of large blood volumes. Applied to leukapheresis products from seven metastatic cancer patients, it achieves high CTC yields, reveals intra-patient heterogeneity, and supports paired single-cell DNA/RNA profiling, CNV-confirmed CTC pooling, and whole exome sequencing for comprehensive cancer monitoring.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/tumor-cell-based-liquid-biopsy-using-highthroughput-microfluidic-enrichment-of-entire-leukapheresis-product-received-date-information/370150/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/tumor-cell-based-liquid-biopsy-using-highthroughput-microfluidic-enrichment-of-entire-leukapheresis-product-received-date-information/370150.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are circulating tumor cells (CTCs) currently limited in clinical utility?","Question",{"text":63,"@type":64},"CTCs are rare in blood, which restricts reliable quantitation and single-cell level analysis. Standard blood tubes may yield very few or no detectable CTCs in many patients depending on assay sensitivity.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What technology is introduced to improve CTC collection for liquid biopsy?",{"text":68,"@type":64},"A highthroughput microfluidic device depletes hematopoietic cells through high-flow channels and uses force-amplifying magnetic lenses to enrich intact CTCs from large blood volumes.",{"name":70,"@type":61,"acceptedAnswer":71},"What analyses become possible after highthroughput CTC enrichment?",{"text":72,"@type":64},"Enriched patient-derived CTCs enable paired single-cell DNA and RNA sequencing to identify subclonal patterns and signaling differences, as well as CNV-confirmed pooling for whole exome sequencing with higher mutant allele fractions.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370150,1790286229,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":128,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Article [https://doi.org/10.1038/s41467-024-55140-x](https://doi.org/10.1038/s41467-024-55140-x)  \nTumor cell-based liquid biopsy using highthroughput microﬂuidic enrichment of entire leukapheresis product  \nReceived: 12 April 2024  \n\n| Accepted: 28 November 2024 |\n| --- |\n| |\n| Check for updates |\n\nAvanish Mishra1,2,10, Shih-Bo Huang 2,3,10, Taronish Dubash2, Risa Burr2, Jon F. Edd1,2, Ben S. Wittner 2, Quinn E. Cunneely1,2, Victor R. Putaturo1,2, Akansha Deshpande1,2, Ezgi Antmen1,2, Kaustav A. Gopinathan 1,2,  \nKeisuke Otani 2,4, Yoshiyuki Miyazawa 2,4, Ji Eun Kwak2, Sara Y. Guay2, Justin Kelly2,4, John Walsh1,2, Linda T. Nieman2, Isabella Galler5, PuiYee Chan5, Michael S. Lawrence 2,6,7, Ryan J. Sullivan 5, Aditya Bardia5,8,  \nDouglas S. Micalizzi2,5, Lecia V. Sequist5, Richard J. Lee5, Joseph W. Franses5, David T. Ting 2,5, Patricia A. R. Brunker6, Shyamala Maheswaran2,  \nDavid T. Miyamoto 2,4,7 , Daniel A. Haber 2,3,5  & Mehmet Toner 1,9   \nCirculating Tumor Cells (CTCs) in blood encompass DNA, RNA, and protein biomarkers, but clinical utility is limited by their rarity. To enable tumor epitope-agnostic interrogation of large blood volumes, we developed a highthroughput microﬂuidic device, depleting hematopoietic cells through highﬂow channels and force-amplifying magnetic lenses. Here, we apply this technology to analyze patient-derived leukapheresis products, interrogating a mean blood volume of 5.83 liters from seven patients with metastatic cancer. High CTC yields (mean 10,057 CTCs per patient; range 100 to 58,125) reveal considerable intra-patient heterogeneity. CTC size varies within patients, with 67% overlapping in diameter with WBCs. Paired single-cell DNA and RNA sequencing identiﬁes subclonal patterns of aneuploidy and distinct signaling pathways within CTCs. In prostate cancers, a subpopulation ofsmall aneuploid cells lacking epithelial markers is enriched for neuroendocrine signatures. Pooling of CNV-conﬁrmed CTCs enables whole exome sequencing with high mutant allele fractions. High-throughput CTC enrichment thus enables cellbased liquid biopsy for comprehensive monitoring of cancer.  \nLiquid biopsies provide increasingly important non-invasive strategies for longitudinal monitoring of cancer, guiding personalized therapies as tumor cells evolve under selective pressures1. DNA sequencingbased analyses of tumor-derived circulating DNA fragments (ctDNA)  \nnow enable the detection of drug-sensitizing and drug-resistant mutations, and they are being tested to detect minimal residual disease following surgery and early recurrence based on mutational or DNA methylation abnormalities2–4. However, ctDNA does not inform  \n1Center for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. 2Krantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129, USA. 3Howard Hughes Medical Institute, Bethesda, MD 20815, USA. 4Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. 5Division of Hematology Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA. 6Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. 7Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. 8Hematology/Oncology, University of California, Los Angeles, USA. 9Shriners Children’s Boston, Boston, MA 02114, USA. 10These authors contributed equally: Avanish Mishra, Shih-Bo Huang. e-mail: [dmiyamoto@mgh.harvard.edu](dmiyamoto@mgh.harvard.edu); [DHABER@mgh.harvard.edu](DHABER@mgh.harvard.edu); [mehmet_toner@hms.harvard.edu](mehmet_toner@hms.harvard.edu)  \ntumor-derived transcriptional signals or cell surface protein biomarkers, whose relevance to cancer immunotherapy and antibodydrug conjugates is rapidly emerging. In addition, ctDNA measurements reﬂect bu","cbCaimgD1sYLicwB","https://ap.wps.com/l/cbCaimgD1sYLicwB","pdf",7605893,"English","# Introduction\n## Limitations of ctDNA and current CTC detection\n## Need for reliable cell-based liquid biopsy\n## Proposed microfluidic CTC enrichment approach\n# Methods and device overview\n## Hematopoietic cell depletion with microfluidics and magnetic lenses\n# Results and applications\n## High CTC yields and heterogeneity assessment\n## Single-cell DNA/RNA and exome sequencing from enriched CTCs","[{\"question\":\"Why are circulating tumor cells (CTCs) currently limited in clinical utility?\",\"answer\":\"CTCs are rare in blood, which restricts reliable quantitation and single-cell level analysis. Standard blood tubes may yield very few or no detectable CTCs in many patients depending on assay sensitivity.\"},{\"question\":\"What technology is introduced to improve CTC collection for liquid biopsy?\",\"answer\":\"A highthroughput microfluidic device depletes hematopoietic cells through high-flow channels and uses force-amplifying magnetic lenses to enrich intact CTCs from large blood volumes.\"},{\"question\":\"What analyses become possible after highthroughput CTC enrichment?\",\"answer\":\"Enriched patient-derived CTCs enable paired single-cell DNA and RNA sequencing to identify subclonal patterns and signaling differences, as well as CNV-confirmed pooling for whole exome sequencing with higher mutant allele fractions.\"}]","Tumor cell-based liquid biopsy using highthroughput microfluidic enrichment of entire leukapheresis product - Received date information | PDF",1790187084,48,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/37a29d956ca98c7e7ce875e355eb3e20.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a310cdfe8ddbfa4a9d6a957496e77351.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc3510d65af7cc0b1e9e5e23e2a3a80a.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d7f4537ead3c0e47770f0a9ab6f22fd.webp",980,1301]